Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference24 articles.
1. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes;Romera;Diabetes Ther,2019
2. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity;Jepsen;Expert Opin Emerg Drugs,2021
3. Standards of care in diabetes—2023: abridged for primary care providers;Clin Diabetes,2022
4. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications;Brown;Lancet,2021
5. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023;ElSayed;Diabetes Care,2023
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions;The Lancet Gastroenterology & Hepatology;2024-10
2. Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity;Current Diabetes Reviews;2024-10
3. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13
4. Obesity in adults;The Lancet;2024-09
5. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3